|
Ryuji Ueno, MD, PhD, PhD – Board Director
Ryuji Ueno is an internationally recognized expert in the pharmacology, physiology and biochemistry of naturally occurring (endogenous) fatty acids and their related compounds.
In the 1980s, Dr. Ueno started pharmaceutical development based on his research with prostones, a class of functional fatty acids whose tremendous therapeutic potential Dr. Ueno first identified. This class of lipids is the subject of over 650 patents worldwide, which are now held by the Sucampo Group. Joined by Dr. Sachiko Kuno in the mid-1980s, after 10 years of biomedical research, Dr. Ueno founded the first Sucampo Group member R-Tech Ueno, Ltd. in Japan, a company dedicated to the research and production of his proprietary compounds.
Following R-Tech Ueno, Ltd's successful development and the commercial launch of RESCULA® eye drops for glaucoma, Dr. Ueno and Dr. Kuno founded Sucampo Pharmaceuticals, Inc. as R-Tech Ueno (USA), Inc. in 1996 to pursue research and development efforts in the Americas.
As a leading expert in his field, Dr. Ueno has authored more than 100 articles in notable scientific journals. Dr. Ueno received his M.D. and a Ph.D. in medical chemistry from Keio University in Japan. Additionally, he holds a Ph.D. in pharmacology from Osaka University.
Alan Chalmers, BSc., PhD, MRPharmS –
Board Director
 Dr. Chalmers works as a regulatory and scientific consultant to
Sucampo Pharma Europe. With over 25 years of pharmaceutical industry
experience mainly in product development, especially in international
regulatory affairs, Dr. Chalmers overseas regulatory aspects of
pre-clinical and clinical programs, and create the most effective
regulatory strategies for Sucampo Pharma Europe’s R&D
programs. Dr. Chalmers holds BSc in pharmacy from University of Strathclyde
in Scotland, U.K. and PhD in Pharmaceutical Technology from the
Victoria University of Manchester, U.K.
Gayle R. Dolecek – P.D., M.P.H. – Board Director
Dr. Dolecek joined Sucampo Pharma Europe’s Board of Director’s in August 2008 and has been Sucampo’s Senior Vice President of Research & Development since May 2006. Dr. Dolecek has worked with Sucampo since its founding in 1996, first as a consultant with the ACC Consulting Group and subsequently as head of Research and Development. Dr. Dolecek guided the development of Sucampo’s regulatory strategy, ensuring compliance with FDA’s complex requirements and played an instrumental role in establishing the Research and Development department. He played a critical role in the April 2008 approval of AMITIZA® for Irritable Bowel Syndrome with constipation in the US, and helped guide the regulatory submissions of AMITIZA® in Europe. From August 1995 to April 2006, Dr. Dolecek was a Senior Consultant at AAC Consulting Group, Inc., a provider of regulatory consulting services to the pharmaceutical industry. Prior to 1995, Dr. Dolecek was an officer with the U.S. Public Health Service where he served in pharmacy and health service related positions. He completed his 30 year career with the government in the Food and Drug Administration as Director of Compendial Operations in the Center for Drug Evaluation and Research. Dr. Dolecek received his B.S. Pharmacy Doctor from the University of Maryland and earned an M.P.H. in Health Services and Planning from the University of Hawaii.
 |
